The Lyme disease treatment market deals with diagnostic and therapeutic options available for treating Lyme disease. Lyme disease is a tick-borne infection caused by the Borrelia burgdorferi bacterium. Symptoms of Lyme disease include rashes, fever, fatigue, joint pains, and neurological problems. If left untreated, the infection can spread to joints, heart, and nervous system. The treatment options for Lyme disease include doxycycline, amoxicillin, and cefuroxime axetil. Non-antibiotic treatments such as corticosteroids and anticonvulsants are also used when Lyme disease infection spreads to joints and nervous system. The rising prevalence of Lyme disease around the world is driving the demand for various diagnostic tests and therapeutic drugs for its treatment.
The global Lyme disease treatment market is estimated to be valued at US$ 1.8 Mn in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Lyme disease treatment are Umicore N.V., Freeport-McMoRan Inc., Glencore plc, Huayou Cobalt Co., Ltd., Sherritt International Corporation, Jinchuan Group International Resources Co. Ltd., Sumitomo Metal Mining Co., Ltd., Norilsk Nickel, ERAMET SA, Umicore Cobalt & Specialty Materials (formerly known as Cobalt & Specialty Materials). These players are engaged in developing novel diagnostic tests and therapeutic drugs for Lyme disease. Growing research and development activities will lead to the launch of better therapies in the coming years.
Rising awareness regarding early diagnosis and treatment of Lyme disease presents significant growth opportunities for players in the market. As the diagnostic and treatment practices improve, more patients can be targeted, thus expanding the customer base. Moreover, with growing trade agreements, companies are able to penetrate untapped regional markets in the international territories, thus facilitating global expansion.
Market Drivers
Increasing incidence and geographical spread of Lyme disease: According to CDC, approximately 476,000 Americans are diagnosed with Lyme disease each year. As the disease-carrying ticks spread to new regions, more people are at the risk of acquiring Lyme infection. This wide patient pool drives the demand for lyme diagnostic testing and treatment options.
Growing funding for lyme disease research: Various private and public organizations are allocating increased funds for supporting research related to lyme pathogenesis, novel diagnostic techniques, and development of effective therapies. This enables organizations to bring more advanced products in the market.
Market Restrains
Lack of disease awareness: In many parts of the world, Lyme Disease Treatment Market Demand is under-recognized due to low awareness among public and healthcare providers. This results in underdiagnosis and delays treatment initiation.
Difficulty in diagnosing chronic Lyme disease: In some patients, the symptoms of Lyme disease may persist for months after antibiotic treatment. However, blood tests currently available lack reliability in diagnosing chronic or post-treatment Lyme disease. This creates a challenge for clinicians in effectively managing such cases.
Segment Analysis
The Lyme disease treatment market is majorly dominated by the antibiotics sub-segment. This is because antibiotics like doxycycline and amoxicillin are currently the standard treatment for Lyme disease approved by the US FDA. They are the first line of treatment for most patients in the early localized stage. These antibiotics are highly effective if caught and treated early. The alternative medicine sub-segment is emerging owing to the increasing demand for natural and herbal alternatives to allopathic antibiotics. Natural products are gaining popularity as they are preferred options due to lesser side effects.
Global Analysis
The North America region dominates the global Lyme disease treatment market currently. This is attributed to the high Lyme disease incidence rates in the United States, more awareness regarding early diagnosis and treatment, and well-established healthcare infrastructure. According to CDC, the states with the highest reported number of cases are Massachusetts, Pennsylvania, New Jersey, Wisconsin, Connecticut etc. Europe is anticipated to be the fastest growing region during the forecast period. This is owing to conducive regulatory guidelines and reimbursement scenarios, strategic developments by market players. The rising numbers of tick-borne diseases are also expected to boost the demand.
Explore more information on this topic, Please visit-
https://www.insightprobing.com/lyme-disease-treatment-market-growth-and-trnds-analysis-share-size-demand-forecast/
Comments
0 comment